Nivolumab Immunotherapy Preparation from United States
A mixed nivolumab monoclonal antibody product for PD-1 inhibition in cancer immunotherapy, supplied in bulk for clinical trials. It is not put up in measured doses or retail packings, and is classified as a mixed immunological product per chapter note 2.
Duty Rate — United States → Canada
0%
Import Tips
• Confirm the product is a mixture containing nivolumab MABs, as defined in chapter note 2
• Ensure it is not in retail packings
• Keep detailed composition records for CBSA verification